Aegea Biotechnologies, Inc. Advances to Semi-Finals of the $5M XPRIZE Rapid COVID Testing Competition
The $5 million, XPRIZE Rapid COVID Testing competition was launched this summer to accelerate the development of high-quality COVID-19 testing that is affordable, easy to use, and that has a fast-turnaround time.
- The $5 million, XPRIZE Rapid COVID Testing competition was launched this summer to accelerate the development of high-quality COVID-19 testing that is affordable, easy to use, and that has a fast-turnaround time.
- A goal of the XPRIZE Rapid COVID Testing competition is to increase the scale of COVID-19 testing capabilities by a hundredfold over our current standard, in order to more safely return to everyday activities.
- Approximately 700 teams spanning six continents registered for the XPRIZE Rapid COVID Testing competition.
- Aegea advanced to the XPRIZE Rapid COVID Testing Semi-Finals after sharing results of a new, highly sensitive, quantitative PCR-based assay for detecting SARS-CoV-2 (COVID-19 virus) that Aegea designed and is developing and validating clinically in collaboration with Biocept, Inc. (NASDAQ:BIOC).